Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 1.00 |
| ▸ | MAPT | P10636 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 11/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 11/20 | 1.00 |
| ▸ | POLB | P06746 | 10/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | HPGD | P15428 | 8/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 8/20 | 1.00 |
| ▸ | BLM | P54132 | 7/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 1.00 |
| ▸ | RECQL | P46063 | 6/20 | 1.00 |
| ▸ | NR4A1 | P22736 | 5/20 | 1.00 |
| ▸ | THRB | P10828 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | PTPN7 | P35236 | 3/20 | 1.00 |
| ▸ | DUSP3 | P51452 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6722302 | 0.79 | MCL1 (0.77) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL20919142 | 0.78 | MEN1 (0.72) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL30518187 | 0.78 | MEN1 (0.72) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL24277667 | 0.78 | MCL1 (1.00) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL6262114 | 0.75 | MEN1 (0.71) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL6262120 | 0.75 | MEN1 (1.00) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL31582586 | 0.75 | ALDH1A1 (0.62) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL13856422 | 0.75 | MEN1 (1.00) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL8290697 | 0.73 | HPGD (0.64) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL20919662 | 0.73 | MEN1 (0.57) | ALDH1A1MAPTMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | claimed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | THE BURNHAM INSTITUTE (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | THE BURNHAM INSTITUTE (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | MCL1, AS3MT, MYADM | ALDH1A1 210/4885MAPT 4723/4885MEN1 1901/4885 |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | BCL2, BAX, BAD | ALDH1A1 3724/4885MAPT 3866/4885MEN1 4323/4885 |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | MCL1, AS3MT, MYADM | ALDH1A1 210/4885MAPT 4723/4885MEN1 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.